2017
DOI: 10.1016/j.jtho.2016.09.001
|View full text |Cite
|
Sign up to set email alerts
|

EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors

Abstract: Taking into account the small number of patients in this study, PFS in patients with EGFR co-mutation appeared significantly shorter, and response rate significantly lower, than in patients with a single mutation. Data from multipanel testing may identify subgroups of patients who are likely to respond poorly to standard treatment. Clarification of these subgroups may improve patient care.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
48
1

Year Published

2018
2018
2024
2024

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 56 publications
(52 citation statements)
references
References 18 publications
3
48
1
Order By: Relevance
“…However, the objective response rate to TKIs was not significantly different. Interestingly, in the report from Barnet and colleagues, patients with co‐occurrence of EGFR mutation, especially PIK3CA mutation, had significantly shorter PFS (5.7 vs. 12.3 months) and inferior response rate (38% vs. 89%) to TKIs than those without .…”
Section: Discussionmentioning
confidence: 98%
“…However, the objective response rate to TKIs was not significantly different. Interestingly, in the report from Barnet and colleagues, patients with co‐occurrence of EGFR mutation, especially PIK3CA mutation, had significantly shorter PFS (5.7 vs. 12.3 months) and inferior response rate (38% vs. 89%) to TKIs than those without .…”
Section: Discussionmentioning
confidence: 98%
“…Yet, p.G719C and p.S768I may coexist more frequently than other rare mutations in NSCLC [ 16 , 18 ]. Moreover, patients with EGFR co-mutations exhibit shorter PFS and lower RR than patients with single EGFR -mutations [ 19 ]. Although S768I alone or concomitant with exon 18 G719X does not necessarily appear to be sensitive to erlotinib [ 16 , 17 ] it was shown to respond to afatinib [ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%
“…Actually in Tunisia, chemotherapy is the primary treatment for NSCLC. Our aim was to estimate the relevance of proposing TKIs for our patients as a new therapeutic line since patients harboring activating EGFR mutations can benefit from treatment with molecules like gefitinib and erlotinib [ 26 , 30 ].…”
Section: Discussionmentioning
confidence: 99%